EP Patent

EP3426316B1 — Delivery of nitric oxide-releasing phospholipids, liposomes, and high density lipoprotein-like nanoparticles (hdl nps) by drug eluting stents and intra-arterial injection

Assigned to Nanyang Technological University · Expires 2023-10-25 · 3y expired

What this patent protects

Patent listed against berdazimer-sodium.

Drugs covered by this patent

Patent Metadata

Patent number
EP3426316B1
Jurisdiction
EP
Classification
—
Expires
2023-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Nanyang Technological University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.